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eply
e thank the 2 authors for their interest in our review (1), in
hich a number of issues were raised regarding definition, possible
auses, detection, and treatment of “aspirin resistance.” The
mergence of the latter requires, first of all, the selection of specific,
eproducible, simple, and standardized platelet function tests that
ould distinguish patients responding to COX-1–related aspirin
ffects from those patients in whom the administration of aspirin
ails to inhibit production of thromboxane A2 through COX-1–
elated pathway(s). The latter is viewed by us as a true incident of
laboratory aspirin resistance.”
The most specific test for the assessment of aspirin effects is
ight transmission platelet aggregometry with low concentrations
f arachidonic acid and adenosine diphosphate. This method is
idely used in almost all large prospective studies of aspirin
esistance and is closely associated with occurrence of cardiovas-
ular events. Its use allows the clinician to assess platelet function
y forming macroaggregates of platelets and is characterized by
ore serious limitations. First and foremost, platelet aggregometry
equires the use of different agonists at different concentrations and
heir (ex vivo) addition to platelet-rich plasma. A frequently used
gonist, arachidonic acid, has been criticized for its possible lytic
ffects on platelets, resulting in an increase of the light transmis-
ion through platelets suspension without an increase in the level
f macroaggregates (2). Another frequently used agonist, adeno-
ine diphosphate at low concentrations, can partly activate the
rachidonic acid cascade, but its main effect is not specific for the
OX-1 pathway. Also, the adjustment of platelet count in
latelet-rich plasma by adding autologous platelet-poor plasma,
hich is mandatory for platelet aggregometry, can itself suppress
latelet function (3). Thus, laboratory preparation and the use of
gonists for platelet aggregometry can cause unpredictable results,
ar from reflecting true platelet function per se in cardiovascular
isease patients taking aspirin.
Thus, we would agree with the comments that we should avoid
he use of agonists for the “ideal test” of aspirin resistance, but this
uggestion probably requires the revision of the current definition
f “laboratory aspirin resistance.” From the physiological point of
iew, platelet aggregometry in platelet-rich plasma is also an in
itro time-consuming test that neglects interactions of platelets
ith leucocytes and erythrocytes at the time of blood sampling.
his problem is partly overcome with the use of whole blood
ggregometry and semiautomated point-of-care platelet function
ssays that use whole blood (e.g., the PFA-100 test, Siemens
ealth Diagnostics, Newark, Delaware), which again exhibits a
umber of other limitations.
It was thought that the use of light transmission aggregometry
n combination with other platelet function tests could avoid the
imitations of different tests and provide a comprehensive assess- dent of platelet function. However, this alternative approach raises
nother important question as to how interpret different, and
ometimes polarized, results of different tests. One of the latest
tudies (4) assessing the prevalence of aspirin resistance with
everal major platelet function tests (e.g., light transmission aggre-
ometry, whole blood aggregometry, PFA-100, VerifyNow-
spirin [Accumetrics, San Diego, California], and urinary 11-
ehydrothromboxane B2) yielded a prevalence ranging from 6.7%
by VerifyNow-Aspirin) to 59.5% (by PFA-100). These results
gain confirm the lack of correlation between laboratory tests of
spirin resistance.
We would agree with the comments that flow cytometry is an in
ivo quantitative test for the detection of activated platelets and
elease of microparticles with the surface markers specific for
hromboxane A2 pathway at an early stage of platelet activation,
nd that it may be viewed as an important tool for future studies on
rue prevalence of “laboratory aspirin resistance.” Nonetheless, the
xpense of flow cytometry and the need to assay samples in
ighly-specialized laboratory centers would make it difficult to
mploy flow cytometry in large-scale prospective studies.
Finally, we agree with Kapoor on the suggestion that there is
ncomplete suppression of platelet aggregation with enteric-coated
spirin. Nonetheless, we should not lose sight of the fact that one
ommon explanation for aspirin resistance, whether defined as
aboratory resistance or clinical resistance (i.e., increased throm-
otic events), is noncompliance (5).
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Ib or Not IIb
hite et al. (1) present an interesting case for the ability to switch
o bivalirudin therapy from heparin (unfractionated heparin or
noxaparin) in non–ST-segment elevation acute coronary syn-
rome. The baseline characteristics of the 2 groups (consistent vs.
s
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October 7, 2008:1276–8witched), however, show a statistically greater proportion of
igh-risk patients in the consistent treatment group (see Table 1 of
hite et al. [1]). Thus, similarity of the 2 groups is not a strength
f the study as suggested.
Removal of the bivalirudin plus glycoprotein (GP) IIb/IIIa
roup from this post-hoc analysis effectively removes a large
opulation that could have increased bleeding complications, and
t would be interesting to see whether the end points could be
aintained if the switch from heparin to bivalirudin plus GP
Ib/IIIa inhibitors was added to the population studied.
Bivalirudin was compared with heparin plus a GP IIb/IIIa
nhibitor. Although recommended by guidelines, in the setting
escribed, the proportion of patients being placed on GP IIb/IIIa
nhibitors in real-world practice is much lower (i.e., approximately
5% in the U.S. [2] and 5% in Australia [3]).
Although one could expect some mortality benefit in the
witched group, because of reduced bleeding over a length of time
s in the ISAR (Innovative Stratification of Arrhythmic Risk) trials
4), the cost effectiveness of bivalirudin is a critical question when
onsidering popular use.
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eply
e would like to thank Drs. Mishra and Walters for their interest
n our work (1). As they accurately point out, there were differences
n 2 of the more than 20 baseline characteristics. However,
lthough patients in the heparin plus glycoprotein IIb/IIIa inhib-
tor (GPI) group more frequently had increased creatine kinase-
yocardial band, troponin levels, or electrocardiogram changes,
ultivariate logistic regression confirmed the results of the uni-
ariate analysis. This adjusted analysis demonstrated that switch-
ng from heparin plus a GPI to bivalirudin monotherapy resulted
n similar rates of composite ischemia (odds ratio [OR]: 0.97; 95%
onfidence interval [CI]: 0.76 to 1.23; p  0.77), and significantlyess non-coronary artery bypass graft major bleeding (OR: 0.47;
5% CI: 0.34 to 0.66; p  0.0001) and net clinical events (OR:
.76; 95% CI: 0.62 to 0.94; p  0.01).
Regarding why we elected not to display the results of the
ivalirudin plus GPI group, in the main ACUITY (Acute Cath-
terization and Urgent Intervention Triage Strategy) trial (2),
ivalirudin plus GPI showed no incremental benefit over bivaliru-
in alone in terms of reducing ischemia but did result in more
leeding. Given these facts, the more expensive bivalirudin plus
PI regimen is unlikely to enter routine clinical practice and, thus,
e did not include these data in the article.
The third point Drs. Mishra and Walters make is that the
CUITY trial was designed to assess the addition of a treatment
bivalirudin) to guideline-recommended therapy. We believe that
his is the appropriate way to perform trials; it would be detrimen-
al for patients to test new treatments in the absence of guideline-
ecommended therapies.
Finally, in respect to cost effectiveness, preliminary analysis
hows bivalirudin to be very cost effective. A prospective analysis
3) showed that 30-day costs were lowest with bivalirudin mono-
herapy compared with heparin plus GPI (cost savings ranging
rom $123 per patient with bivalirudin monotherapy vs. heparin
PI administration in the catheterization laboratory to $422 per
atient with bivalirudin monotherapy vs. heparin  upstream
PI).
Thus, adjusted analysis of the switch cohort demonstrates that
he results with bivalirudin monotherapy remain consistent despite
light differences in baseline characteristics. The present study
upports the safety and efficacy of switching to bivalirudin from
nfractionated heparin or enoxaparin in moderate- and high-risk
atients with non–ST-segment elevation acute coronary syn-
romes and preserves the 50% reduction in major bleeding seen
ith bivalirudin, with comparable rates of ischemia and, thus,
mproved overall patient outcomes.
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